Wells Fargo analyst Derek Archila lowered the firm’s price target on Soleno Therapeutics (SLNO) to $106 from $123 and keeps an Overweight rating on the shares. The firm says that while this is not the quarter it hoped for exactly, Wells still thinks Vykat XR will be a $1B-plus drug in Prader-Willi syndrome. The firm expects shares to be volatile through year-end 2025 on competitor data but sees the opportunity for shares to outperform on Q4 revenues amid low expectations.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics Achieves Profitability with VYKAT XR Launch
- Soleno Therapeutics: Strong Sales Growth and Profitability Drive Buy Rating
- Closing Bell Movers: AMD falls 4% on earnings, Trex, Pinterest down sharply
- Soleno Therapeutics reports Q3 EPS 47c, consensus 6c
- Soleno Therapeutics options imply 15.9% move in share price post-earnings